Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Total Liabilities (2020 - 2025)

Historic Total Liabilities for Maravai Lifesciences Holdings (MRVI) over the last 6 years, with Q3 2025 value amounting to $417.3 million.

  • Maravai Lifesciences Holdings' Total Liabilities fell 3729.57% to $417.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $417.3 million, marking a year-over-year decrease of 3729.57%. This contributed to the annual value of $431.0 million for FY2024, which is 3820.87% down from last year.
  • Per Maravai Lifesciences Holdings' latest filing, its Total Liabilities stood at $417.3 million for Q3 2025, which was down 3729.57% from $429.0 million recorded in Q2 2025.
  • In the past 5 years, Maravai Lifesciences Holdings' Total Liabilities ranged from a high of $1.4 billion in Q3 2021 and a low of $417.3 million during Q3 2025
  • Moreover, its 5-year median value for Total Liabilities was $1.3 billion (2021), whereas its average is $1.0 billion.
  • Its Total Liabilities has fluctuated over the past 5 years, first soared by 2302.71% in 2021, then tumbled by 5283.6% in 2024.
  • Maravai Lifesciences Holdings' Total Liabilities (Quarter) stood at $1.4 billion in 2021, then grew by 0.3% to $1.4 billion in 2022, then plummeted by 49.34% to $697.6 million in 2023, then plummeted by 38.21% to $431.0 million in 2024, then fell by 3.18% to $417.3 million in 2025.
  • Its last three reported values are $417.3 million in Q3 2025, $429.0 million for Q2 2025, and $429.5 million during Q1 2025.